Welcome to CDC Stacks | Use of anthrax vaccine in the United States; recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 - 5702 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Use of anthrax vaccine in the United States; recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
  • Published Date:
    July 23, 2010
Filetype[PDF - 478.63 KB]


Details:
  • Corporate Authors:
    United States, Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) ; National Center for Immunization and Respiratory Diseases (U.S.), Division of Bacterial Diseases. ; ... More ▼
  • Pubmed ID:
    20651644
  • Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-6
  • Document Type:
  • Description:
    "These recommendations from the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations for anthrax vaccine adsorbed (AVA) (CDC). Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2000;49:1-20; CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2002;51:1024-6) and reflect the status of anthrax vaccine supplies in the United States. This statement 1) provides updated information on anthrax epidemiology; 2) summarizes the evidence regarding the effectiveness and efficacy, immunogenicity, and safety of AVA; 3) provides recommendations for pre-event and preexposure use of AVA; and 4) provides recommendations for postexposure use of AVA. In certain instances, recommendations that did not change were clarified. No new licensed anthrax vaccines are presented. Substantial changes to these recommendations include the following: 1) reducing the number of doses required to complete the pre-event and preexposure primary series from 6 doses to 5 doses, 2) recommending intramuscular rather than subcutaneous AVA administration for preexposure use, 3) recommending AVA as a component of postexposure prophylaxis in pregnant women exposed to aerosolized Bacillus anthracis spores, 4) providing guidance regarding preexposure vaccination of emergency and other responder organizations under the direction of an occupational health program, and 5) recommending 60 days of antimicrobial prophylaxis in conjunction with 3 doses of AVA for optimal protection of previously unvaccinated persons after exposure to aerosolized B. anthracis spores." - p. 1

    Includes bibliographical references (p. 23-29).

  • Supporting Files:
    No Additional Files